As blockbuster drugs are replaced by collections of micro products, companies must build brand plans for an increasingly diverse array of products while also coalescing these brand plans so that they enable success across their portfolios. In PharmaLive, Rohit Gupta and Dan Wetherill discuss how companies can enrich their brand plans and turn them into drivers of business success.